Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (451-460 of 520) with videos related to

Pageof 52
Sort By:
Journal of the American College of Cardiology|August 1, 2020
Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEFJonathan W Cunningham, Brian L Claggett, Eileen O'Meara, et al.
JACC. Heart Failure|May 11, 2020
Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical TrialsJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
Circulation|April 13, 2011
Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trialAndrew G Bostom, Myra A Carpenter, John W Kusek, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 11, 2017
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKDDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.
Journal of the American College of Cardiology|May 24, 2023
Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection FractionRiccardo M Inciardi, Martin Abanda, Amil M Shah, et al.
Circulation. Heart Failure|April 18, 2018
Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure TrialEldrin F Lewis, Brian Claggett, Amil M Shah, et al.
Kidney International. Supplement|October 16, 2004
Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuriaNagesh S Anavekar, Daniel J Gans, Tomas Berl, et al.
JACC. Heart Failure|July 11, 2021
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF TrialMauro Gori, Michele Senni, Brian Claggett, et al.
European Journal of Heart Failure|March 27, 2020
Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndromeSung-Hee Shin, Brian Claggett, Marc A Pfeffer, et al.
European Heart Journal|April 21, 2017
Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trialsAzmil H Abdul-Rahim, Ana-Cristina Perez, Rachael L MacIsaac, et al.
Pageof 52

Showing results (451-460 of 520) with videos related to

Sort By:
Pageof 52
Journal of the American College of Cardiology|August 1, 2020
Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEFJonathan W Cunningham, Brian L Claggett, Eileen O'Meara, et al.
JACC. Heart Failure|May 11, 2020
Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical TrialsJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
Circulation|April 13, 2011
Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trialAndrew G Bostom, Myra A Carpenter, John W Kusek, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 11, 2017
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKDDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.
Journal of the American College of Cardiology|May 24, 2023
Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection FractionRiccardo M Inciardi, Martin Abanda, Amil M Shah, et al.
Circulation. Heart Failure|April 18, 2018
Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure TrialEldrin F Lewis, Brian Claggett, Amil M Shah, et al.
Kidney International. Supplement|October 16, 2004
Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuriaNagesh S Anavekar, Daniel J Gans, Tomas Berl, et al.
JACC. Heart Failure|July 11, 2021
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF TrialMauro Gori, Michele Senni, Brian Claggett, et al.
European Journal of Heart Failure|March 27, 2020
Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndromeSung-Hee Shin, Brian Claggett, Marc A Pfeffer, et al.
European Heart Journal|April 21, 2017
Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trialsAzmil H Abdul-Rahim, Ana-Cristina Perez, Rachael L MacIsaac, et al.
Pageof 52